Eli Lilly and Company (LLY)

LLY (NYSE:Drugs)
$55.90
neg -0.04
-0.07%
Today's Range: 55.35 - 56.23 | LLY Avg Daily Volume: 5,136,800
Last Update: 05/17/13 - 4:02 PM EDT
Volume: 3,763,076
YTD Performance: 13.34%
Open: $55.97
Previous Close: $55.94
52 Week Range: $39.93 - $58.41
Oustanding Shares: 1,126,561,464
Market Cap: 63,019,848,296
6-Month Chart
TheStreet Ratings Grade for LLY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 5 5 5
Moderate Buy 0 0 0 0
Hold 7 7 7 8
Moderate Sell 1 1 1 1
Strong Sell 3 3 3 2
Mean Rec. 2.77 2.77 2.77 2.64
Latest Dividend: 0.49
Latest Dividend Yield: 3.50%
Dividend Ex-Date: 05/14/13
Price Earnings Ratio: 13.41
Price Earnings Comparisons:
LLY Sector Avg. S&P 500
13.41 13.40 17.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
4.31% 37.92% 64.36%
GROWTH 12 Mo 3 Yr CAGR
Revenue -6.90 0.04 0.01
Net Income 0.00 0.00 0.00
EPS -6.20 -0.07 -0.02
Earnings for LLY:
EBITDA 6.48B
Revenue 22.60B
Average Earnings Estimates
Qtr (06/13) Qtr (09/13) FY (12/13) FY (12/14)
Average Estimate $1.00 $0.94 $3.91 $2.75
Number of Analysts 8 7 12 10
High Estimate $1.05 $0.98 $3.96 $2.90
Low Estimate $0.95 $0.87 $3.85 $2.62
Prior Year $0.83 $0.79 $3.39 $3.91
Growth Rate (Year over Year) 21.08% 19.35% 15.27% -29.60%
Update Chart
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
scripnews
scripnews: RT @ScripDonnaDC: ICYMI: Lilly to CMS: Failure to cover Amyvid will chill Alzheimer's R&D http://t.co/GdfKuqOiQC $LLY #pharma #biotech #biopharma #CMS
2 days ago from web
wjexchange
wjexchange: Commented on: "What Will $2 Million Get You In Retirement?" http://t.co/swHS5YCQp6 $JNJ $KO $LLY $SYY
2 days ago from SeekingAlpha.com
ScripMandy
ScripMandy: RT @ScripDonnaDC: ICYMI: Lilly to CMS: Failure to cover Amyvid will chill Alzheimer's R&D http://t.co/GdfKuqOiQC $LLY #pharma #biotech #biopharma #CMS
2 days ago from web
WealthTrace
WealthTrace: Commented on: "What Will $2 Million Get You In Retirement?" http://t.co/XTUJfTXEQ5 $JNJ $KO $LLY $SYY
2 days ago from SeekingAlpha.com
ScripDonnaDC
ScripDonnaDC: ICYMI: Lilly to CMS: Failure to cover Amyvid will chill Alzheimer's R&D http://t.co/GdfKuqOiQC $LLY #pharma #biotech #biopharma #CMS
2 days ago from web
mjlevy76
mjlevy76: @MDLinx: Treatment with 2 osteoporosis drugs better at increasing bone density than single-drug therapy: http://t.co/Va6KAiJBmv $LLY $AMGN
2 days ago from TweetDeck
w_pat_tc
w_pat_tc: WO2013070460A1 Combination Therapy For Ovarian Cancer $LLY #A61K #A61K31 http://t.co/SAQWPbH3Ol
2 days ago from TwittlyDumb
scripnews
scripnews: Nevertheless should we expect a no decision? “@ScripDonnaDC: @ScripMikeWard No decision yet. $LLY worried #CMS may not reimburse #Amyvid"
2 days ago from Twitter for iPad
scripnews
scripnews: RT @ScripMikeWard: As test binary & disease burden is a spectrum is #CMS decision surprising? "@ScripDonnaDC: $LLY on not covering Amyvid on #Alzheimer's R&D"
2 days ago from Twitter for iPad
medtech_ma
medtech_ma: RT @ScripDonnaDC: @ScripMikeWard No decision yet. $LLY saying 'if' CMS fails to reimburse for Amyvid, the consequence. Decision expected late June/early July.
2 days ago from web

Time to Cash In on Actavis

By

John Dorfman

 | May 13, 2013 | 9:00 AM EDT

Here are seven reasons why.

updateLLY Investor Mtg.

May 6, 2013 | 7:02 AM EDT

LLY - Eli Lilly Annual Shareholder Meeting - 11AM

It's Pipeline That Matters Most

By

Jim Cramer

 | May 1, 2013 | 12:49 PM EDT

Focusing on near-term drug stock earnings is the wrong move.

National Lemming Day

By

Jim Cramer

 | Apr 24, 2013 | 1:16 PM EDT

It’s the only thing that explains today’s action.

The Biotech Revaluation Is On

By

Jim Cramer

 | Apr 17, 2013 | 6:20 AM EDT

These four names in particular have made some stunning moves.

Loving the Rally?

By

Gary Dvorchak

 | Mar 11, 2013 | 9:30 AM EDT

Here is how I am picking apart the sectors looking for strong relative performance candidates.

updateCowen Healthcare Conf.

Mar 5, 2013 | 7:05 AM EST

Cowen Health Care Conference (Day 2 of 3) - 03/04/13 - 03/06/13 Boston, MA

Market on Close Imbalances

By

Doug Kass

 | Feb 28, 2013 | 3:56 PM EST
My mavens on the floor of the exchange see $1 billion to sell on the close.

Market on Close Imbalances

By

Doug Kass

 | Feb 15, 2013 | 3:52 PM EST
How much to buy?

Do Your Timely Dividend Research

By

Gary Dvorchak

 | Feb 4, 2013 | 3:44 PM EST

Yields are dwindling, and here are some interesting events occurring in the next couple of weeks.

Columnist Conversation / Market Updates

A Special Thank You to Barron's
By

Brian Sozzi

 | May 18, 2013 | 6:48 AM EDT
I greatly appreciate the team for sharing my remembrance to Alan Abelson. It really did come from the heart. I am becom...

How to Obliterate an Earnings Call
By

Brian Sozzi

 | May 18, 2013 | 6:33 AM EDT
I approach an earnings call as I do eating a lobster: tear it apart and leave nothing for the dogs in the back alley. ...
See more »

Our Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.